As new PrEP products move out of clinical trials and toward market entry, implementation research has a pivotal role to play in guiding the introduction and scale-up of these new products in real-world service delivery settings.
Continue Reading
Category: Product Introduction
CHAMPIONING CHOICE IN A MULTI-PRODUCT HIV PREVENTION MARKET
New products, including the dapivirine vaginal ring and injectable cabotegravir, have been approved in several countries, and more biomedical prevention products are in development. As the catalog of HIV prevention products expands, so too does the conversation about the importance of upholding choice to optimize the benefits for potential PrEP users.
Continue Reading
A NEW OPTION TO TRANSFORM HIV PREVENTION
The future of HIV prevention is here. Injectable cabotegravir (CAB) is the most effective, longest-acting option for avoiding the virus. Until now, pre-exposure prophylaxis (or PrEP) medicine taken to prevent HIV has only been available as an oral pill that must be taken daily. CAB needs to be injected only once every two months.
Continue Reading
SHE DECIDES: SUPPORTING PrEP DECISION-MAKING AMONG ADOLESCENT GIRLS AND YOUNG WOMEN IN A MULTI-PRODUCT PrEP MARKET
As we move toward a multi-product HIV prevention market, adolescent girls and young women must be empowered to choose an HIV prevention product that meets their needs.
Continue Reading
ENABLING CHOICE: FIVE WAYS MOSAIC WILL SUPPORT PrEP POLICYMAKING AND PROGRAMS
For Zimbabwe and other countries in eastern and southern Africa, the emergence of new forms of PrEP presents a remarkable opportunity to offer potential users a range of choices to better meet their HIV prevention needs.
Continue Reading
NOVEL HIV PREVENTION PRODUCTS: EXPANDING THE EVIDENCE FOR INTRODUCTION
When countries introduce novel HIV prevention products, such as the PrEP ring and injectable CAB PrEP, how will women decide which product to use, and what will influence those decisions?
Continue Reading
WHAT’S NEXT FOR CAB PrEP?
In this webinar, we explore ongoing and completed research on CAB PrEP, learn about the recently released FDA guidance, and hear from a panel of implementers and policymakers on what is needed to advance introduction of this new HIV prevention product.
Continue Reading